drugset / Trial / NCT00698568

Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects

NCT00698568

Phase 3 Completed 7460 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

This study will evaluate, versus a placebo, the safety of Herpes simplex candidate vaccine with adjuvant in initially HSV seropositive or seronegative subjects who have no genital herpes disease.

Timeline

Start
1996-10
Primary completion
1999-04
Completion
1999-04

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK208141 Vaccine Intramuscular

Indications

No indication recorded.